Lee Health’s supply of the most effective monoclonal antibody (MAB) treatment for the COVID-19 Omicron variant has been exhausted.

In an email from Lee Health officials on Wednesday, the healthcare system, due to a nationwide shortage, stated they no longer can administer the treatment Sotrovimab.

“Other monoclonal antibodies have been effective against previous variants, but not Omicron,” said Lee Health spokesperson Jonathon Little in the email.

Since Sotrovimab is distributed by the federal government, officials said they are uncertain of when additional supply of the MAB treatment could be available.

“It is more important than ever to get vaccinated or get a booster shot so to protect yourself against COVID-19 during the current Omicron surge,” Little said.

Lee Health has been operating three MAB infusion centers in outpatient settings to treat COVID-19 for more than a year.